JPH10506103A - 4−アルコキシ−n−アセチルノイラミン酸の合成 - Google Patents
4−アルコキシ−n−アセチルノイラミン酸の合成Info
- Publication number
- JPH10506103A JPH10506103A JP8506565A JP50656596A JPH10506103A JP H10506103 A JPH10506103 A JP H10506103A JP 8506565 A JP8506565 A JP 8506565A JP 50656596 A JP50656596 A JP 50656596A JP H10506103 A JPH10506103 A JP H10506103A
- Authority
- JP
- Japan
- Prior art keywords
- group
- acid
- alkoxy
- alkyl
- alkylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 11
- 238000003786 synthesis reaction Methods 0.000 title claims description 9
- 238000000034 method Methods 0.000 claims abstract description 54
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 31
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 31
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 10
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 8
- 238000010511 deprotection reaction Methods 0.000 claims abstract description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- 230000029936 alkylation Effects 0.000 claims description 27
- 238000005804 alkylation reaction Methods 0.000 claims description 27
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 23
- 230000011987 methylation Effects 0.000 claims description 15
- 238000007069 methylation reaction Methods 0.000 claims description 15
- 239000003377 acid catalyst Substances 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 239000012346 acetyl chloride Substances 0.000 claims description 8
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 230000002152 alkylating effect Effects 0.000 claims description 7
- 150000004702 methyl esters Chemical class 0.000 claims description 7
- YKYIFUROKBDHCY-ONEGZZNKSA-N (e)-4-ethoxy-1,1,1-trifluorobut-3-en-2-one Chemical group CCO\C=C\C(=O)C(F)(F)F YKYIFUROKBDHCY-ONEGZZNKSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- -1 p-toluene sulfone Chemical class 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000003729 cation exchange resin Substances 0.000 claims description 3
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 claims description 3
- 229940008406 diethyl sulfate Drugs 0.000 claims description 3
- QUJIVWINNPEYAS-UHFFFAOYSA-N dihexyl sulfate Chemical compound CCCCCCOS(=O)(=O)OCCCCCC QUJIVWINNPEYAS-UHFFFAOYSA-N 0.000 claims description 3
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 claims description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
- 229930194542 Keto Natural products 0.000 claims 2
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims 2
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 claims 2
- 230000001035 methylating effect Effects 0.000 claims 2
- 239000002585 base Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102000005348 Neuraminidase Human genes 0.000 description 13
- 108010006232 Neuraminidase Proteins 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000006200 ethylation reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000051616 Ulmus minor Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000006203 ethylation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006207 propylation Effects 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- JMHJTELEAIHBJT-UHFFFAOYSA-N 5-bromo-4-chloro-1h-indole Chemical compound ClC1=C(Br)C=CC2=C1C=CN2 JMHJTELEAIHBJT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WQLNTUBLQCLIBE-NLKCOZIFSA-N CCO[C@]1(O)CC(O)(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H]1NC(C)=O Chemical compound CCO[C@]1(O)CC(O)(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H]1NC(C)=O WQLNTUBLQCLIBE-NLKCOZIFSA-N 0.000 description 1
- XJAKKVPLKLNDAC-CLLZQFASSA-N CO[C@]1(O)CC(O)(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H]1NC(C)=O Chemical compound CO[C@]1(O)CC(O)(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H]1NC(C)=O XJAKKVPLKLNDAC-CLLZQFASSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000265913 Crataegus laevigata Species 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-ZTVVOAFPSA-N N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-ZTVVOAFPSA-N 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 241000506319 Trifur Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- BQCLJECBJVWSES-UHFFFAOYSA-N acetyl chloride;hydrochloride Chemical compound Cl.CC(Cl)=O BQCLJECBJVWSES-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940062057 nitrogen 80 % Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.4−アルコキシ−N−アセチルノイラミン酸の合成方法であって、以下の工 程を含む該方法: (a) C−1にアルキルエステル及びC−2にアルキルケトシドを有するN−ア セチルノイラミン酸誘導体のC−8及びC−9のビシナルヒドロキシル基を酸触 媒の存在下でケタールを形成することにより保護する工程; (b) 工程(a)により保護された誘導体のC−4をアルキル化して、C−4にア ルコキシ基を形成する工程;及び (c) 工程(b)によりアルキル化された、保護された誘導体を、C−8及びC− 9のケタール除去及びC−1及びC−2のアルキル基除去により脱保護して、4 −アルコキシ−N−アセチルノイラミン酸を形成する工程。 2.ケタールを形成するために使用される酸触媒が、p−トルエンスルホン酸、 p−トルエンスルホン酸塩、ZnCl2及びFeCl3からなる群から選択される 請求項1に記載の方法。 3.酸触媒が、p−トルエンスルホン酸のピリジニウム塩である請求項2に記載 の方法。 4.C−4のアルキル化により、C−4に式RO−(式中、Rは1〜6個の炭素 原子を有するアルキル基である)のアルコキシ基が形成される請求項1に記載の 方法。 5.アルキル化が、ジメチルスルフェート、ジエチルスルフェート、ジプロピル スルフェート、ジブチルスルフェート、ジペンチルスルフェート及びジヘキシル スルフェートからなる群から選択されたアルキル化剤を用いて行われる請求項4 に記載の方法。 6.アルキル化が、約0℃〜約30℃の温度で約10分〜約48時間行われる請 求項4に記載の方法。 7.アルキル化が、約0℃〜約22℃の温度で約10分〜約30分間行われるメ チル化である請求項6に記載の方法。 8.C−8及びC−9のケタール基が、酢酸を用いた処理により除去される請求 項1に記載の方法。 9.C−1及びC−2のアルキル基が、アルカリ処理及びその後の酸水解により 除去される請求項1に記載の方法。 10.4−アルコキシ−N−アセチルノイラミン酸の合成方法であって、以下の工 程を含む該方法: (a) N−アセチルノイラミン酸のC−1のカルボン酸基及びC−2のヒドロキ シル基をアルキル化して、N−アセチルノイラミン酸のアルキルエステルアルキ ルケトシドを形成する工程; (b) アルキルエステルアルキルケトシドのC−8及びC−9のビシナルヒドロ キシル基を、p−トルエンスルホン酸、p−トルエンスルホン酸塩、ZnCl2及びF eCl3からなる群から選択された酸触媒の存在下でケタールを形成することにより 保護する工程; (c) 工程(b)の保護されたアルキルエステルケトシドのC−4のヒドロキシル 基をアルキル化して、C−4にアルコキシ基を形成する工程;及び (d) 工程(c)の生成物のC−8及びC−9に形成されたケタール基を除去し、 かつC−1及びC−2のアルキル基を除去して、4−アルコキシ−N−アセチル ノイラミン酸を得る工程。 11.C−1のカルボン酸基が、触媒の存在下でアルキル化される請求項10に記 載の方法。 12.触媒が、トリフルオロ酢酸及びカチオン交換樹脂からなる群から選択される 請求項11に記載の方法。 13.C−2のヒドロキシル基が、有効量の塩化アセチルの存在下でアルキル化さ れる請求項10に記載の方法。 14.酸触媒が、p−トルエンスルホン酸のピリジニウム塩である請求項10に記 載の方法。 15.C−4のヒドロキシル基をアルキル化して、式RO−(式中、Rは1〜6個 の炭素原子を有するアルキル基である)のアルコキシ基を形成する請求項10に 記載の方法。 16.C−4のアルキル化が、ジメチルスルフェート、ジエチルスルフェート、ジ プロピルスルフェート、ジブチルスルフェート、ジペンチルスルフェート及び ジヘキシルスルフェートからなる群から選択されたアルキル化剤を用いて行われ る請求項15に記載の方法。 17.C−4のアルキル化が、約0℃〜約30℃の温度で約10分〜約48時間行 われる請求項16に記載の方法。 18.C−4のアルコキシ基がメトキシ基であり、かつC−4のアルキル化が約0 ℃〜約22℃の温度で約10分〜約30分間行われる請求項17に記載の方法。 19.C−8及びC−9のケタール基が、酢酸を用いた処理により除去される請求 項10に記載の方法。 20.C−1及びC−2のアルキル基が、アルカリ処理及びその後の酸水解により 除去される請求項10に記載の方法。 21.4−アルコキシ基が4−メトキシ基又は4−エトキシ基である4−アルコキ シ−N−アセチルノイラミン酸の合成方法であって、以下の工程を含む該方法: (a) N−アセチルノイラミン酸のC−1のカルボン酸基を、トリフルオロ酢酸 及びカチオン交換樹脂からなる群から選択された触媒の存在下でメチル化して、 N−アセチルノイラミン酸のメチルエステルを形成する工程; (b) N−アセチルノイラミン酸のメチルエステルのC−2のヒドロキシル基を 、有効量の塩化アセチルの存在下でメチル化して、N−アセチルノイラミン酸の メチルエステルメチルケトシドを形成する工程; (c) メチルエステルメチルケトシドのC−8及びC−9のビシナルヒドロキシ ル基を、p−トルエンスルホン酸、p−トルエンスルホン酸塩、ZnCl2及び FeCl3からなる群から選択された酸触媒の存在下でケタールを形成すること により保護する工程; (d) 保護されたアルキルエステルケトシドのC−4のヒドロキシル基をアルキ ル化して、C−4にメトキシ基又はエトキシ基を形成する工程、ここで該アルキ ル化は約0℃〜約30℃の温度で約10分〜約24時間行われる;及び (e) C−8及びC−9に形成されたケタール基を、酢酸を用いた処理により除 去し、かつC−1及びC−2のメチル基をアルカリ処理及びその後の酸水解によ り除去して、4−アルコキシ−N−アセチルノイラミン酸(該4−アルコキシ基 は4−メトキシ基又は4−エトキシ基である)を得る工程。 22.4−アルコキシ基がメトキシ基であり、かつ工程(d)のアルキル化が約0℃ 〜約22℃の温度で約10分〜約30分間行われる請求項21に記載の方法。 23.4−アルコキシ基がエトキシ基であり、かつ工程(d)のアルキル化が約0℃ 〜約22℃の温度で約1時間〜約24時間行われる請求項21に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/286,573 US5556963A (en) | 1994-08-05 | 1994-08-05 | Synthesis of 4-alkoxy-N-acetylneuraminic acid |
| US08/286,573 | 1994-08-05 | ||
| PCT/US1995/009223 WO1996004291A1 (en) | 1994-08-05 | 1995-07-21 | Synthesis of 4-alkoxy-n-acetylneuraminic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10506103A true JPH10506103A (ja) | 1998-06-16 |
| JP3947218B2 JP3947218B2 (ja) | 2007-07-18 |
Family
ID=23099220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50656596A Expired - Fee Related JP3947218B2 (ja) | 1994-08-05 | 1995-07-21 | 4−アルコキシ−n−アセチルノイラミン酸の合成 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5556963A (ja) |
| EP (1) | EP0775152B1 (ja) |
| JP (1) | JP3947218B2 (ja) |
| AT (1) | ATE180488T1 (ja) |
| AU (1) | AU685312B2 (ja) |
| CA (1) | CA2195872A1 (ja) |
| DE (1) | DE69509903T2 (ja) |
| DK (1) | DK0775152T3 (ja) |
| ES (1) | ES2131841T3 (ja) |
| GR (1) | GR3030713T3 (ja) |
| NO (1) | NO305757B1 (ja) |
| WO (1) | WO1996004291A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663055A (en) * | 1989-12-29 | 1997-09-02 | Oklahoma Medical Research Foundation | Methods for diagnosing human influenza and 4-position modified chromogenic N-acetylneuraminic acid substrated for use therein |
| US5958973A (en) * | 1993-09-03 | 1999-09-28 | Gilead Sciences, Inc. | Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors |
| US5866601A (en) * | 1995-02-27 | 1999-02-02 | Gilead Sciences, Inc. | Carbocyclic compounds |
| CN100409844C (zh) | 1995-02-27 | 2008-08-13 | 吉里德科学公司 | 神经氨酸苷酶抑制剂 |
| US5763483A (en) * | 1995-12-29 | 1998-06-09 | Gilead Sciences, Inc. | Carbocyclic compounds |
| US5891855A (en) | 1996-02-12 | 1999-04-06 | The Scripps Research Institute | Inhibitors of leaderless protein export |
| US6518438B2 (en) | 1996-08-23 | 2003-02-11 | Gilead Sciences, Inc. | Preparation of cyclohexene carboxylate derivatives |
| US5859284A (en) * | 1996-08-23 | 1999-01-12 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
| US5719020A (en) * | 1996-09-25 | 1998-02-17 | Oklahoma Medical Research Foundation | 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens |
| US5994377A (en) * | 1996-10-21 | 1999-11-30 | Gilead Sciences, Inc. | Piperidine compounds |
| US5886213A (en) * | 1997-08-22 | 1999-03-23 | Gilead Sciences, Inc. | Preparation of carbocyclic compounds |
| US20040053999A1 (en) * | 1997-09-17 | 2004-03-18 | Bischofberger Norbert W. | Novel compounds and methods for synthesis and therapy |
| TW477783B (en) * | 1997-12-12 | 2002-03-01 | Gilead Sciences Inc | Novel compounds useful as neuraminidase inhibitors and pharmaceutical compositions containing same |
| US6303764B1 (en) | 1998-09-24 | 2001-10-16 | Zymetx, Inc. | Synthesis of 4,7-dialkyl chromogenic glycosides of N-acetylneuraminic acids |
| EP1185710A2 (en) * | 1999-04-16 | 2002-03-13 | Zymetx, Inc. | Viral detection method using viral encoded enzymes and chemiluminescent substrates |
| US6420552B1 (en) | 1999-09-10 | 2002-07-16 | Zymetx, Inc. | Syntheses of 4-alkyl chromogenic glycosides and 7-alkyl chromogenic glycosides of N-acetylneuraminic acids |
| US9119866B2 (en) | 2008-04-08 | 2015-09-01 | Huiru Wang | Glycan-based drugs, therapies and biomarkers |
| AU2022365434A1 (en) * | 2021-10-14 | 2024-05-02 | Owlstone Medical Limited | Method for the synthesis of evoc probes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3950322A (en) * | 1973-08-27 | 1976-04-13 | Research Corporation | Fluorogenic substrate glycosides |
| US5239091A (en) * | 1988-08-30 | 1993-08-24 | G. D. Searle & Co. | 2-deoxy derivatives of N-acetyl neuraminic acid and their preparation |
| US5191073A (en) * | 1989-02-13 | 1993-03-02 | Miles Inc. | Chromogenic merocyanine enzyme substrates |
| DK0507854T3 (da) * | 1989-12-29 | 1997-05-12 | Oklahoma Med Res Found | Fremgangsmåder til diagnosticering af human-influenza og chromogene N-acetylneuraminsyresubstrater, der er modificerede i 4-positionen, til anvendelse deri |
| AP249A (en) * | 1990-04-24 | 1993-03-17 | Biota Scient Management Pty Ltd | Anti-viral compounds. |
| US5138044A (en) * | 1990-08-13 | 1992-08-11 | Glycomed, Inc. | Synthesis of sialosides |
| WO1992006691A1 (en) * | 1990-10-19 | 1992-04-30 | Biota Scientific Management Pty. Ltd. | Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus |
| US5252458A (en) * | 1990-12-31 | 1993-10-12 | Symex Corp. | Method for visually detecting the presence of a virus in a clinical specimen |
| JPH04300890A (ja) * | 1991-03-29 | 1992-10-23 | Nisshin Oil Mills Ltd:The | シアル酸部分を変換したガングリオシドgm3類縁体 |
-
1994
- 1994-08-05 US US08/286,573 patent/US5556963A/en not_active Expired - Lifetime
-
1995
- 1995-07-21 CA CA002195872A patent/CA2195872A1/en not_active Abandoned
- 1995-07-21 EP EP95926764A patent/EP0775152B1/en not_active Expired - Lifetime
- 1995-07-21 ES ES95926764T patent/ES2131841T3/es not_active Expired - Lifetime
- 1995-07-21 DE DE69509903T patent/DE69509903T2/de not_active Expired - Fee Related
- 1995-07-21 WO PCT/US1995/009223 patent/WO1996004291A1/en not_active Ceased
- 1995-07-21 DK DK95926764T patent/DK0775152T3/da active
- 1995-07-21 AT AT95926764T patent/ATE180488T1/de not_active IP Right Cessation
- 1995-07-21 JP JP50656596A patent/JP3947218B2/ja not_active Expired - Fee Related
- 1995-07-21 AU AU31033/95A patent/AU685312B2/en not_active Ceased
-
1997
- 1997-02-03 NO NO970462A patent/NO305757B1/no not_active IP Right Cessation
-
1999
- 1999-07-07 GR GR990401796T patent/GR3030713T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69509903D1 (de) | 1999-07-01 |
| DK0775152T3 (da) | 1999-11-29 |
| CA2195872A1 (en) | 1996-02-15 |
| NO305757B1 (no) | 1999-07-19 |
| ATE180488T1 (de) | 1999-06-15 |
| JP3947218B2 (ja) | 2007-07-18 |
| US5556963A (en) | 1996-09-17 |
| WO1996004291A1 (en) | 1996-02-15 |
| NO970462D0 (no) | 1997-02-03 |
| AU3103395A (en) | 1996-03-04 |
| NO970462L (no) | 1997-04-07 |
| GR3030713T3 (en) | 1999-11-30 |
| EP0775152B1 (en) | 1999-05-26 |
| EP0775152A1 (en) | 1997-05-28 |
| DE69509903T2 (de) | 1999-10-28 |
| ES2131841T3 (es) | 1999-08-01 |
| AU685312B2 (en) | 1998-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10506103A (ja) | 4−アルコキシ−n−アセチルノイラミン酸の合成 | |
| JP4070817B2 (ja) | 4,7―ジアルコキシ―n―アセチルノイラミン酸誘導体、および臨床的サンプル中のインフルエンザa型およびb型ウィルスの検出法 | |
| EP0064012B1 (fr) | Nouveaux disaccharides formés de motifs à structure glucosamine et acide uronique, leur préparation et leurs applications biologiques | |
| US11629161B2 (en) | Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ß-d-glucopyranos-1-yl)-benzene, L-proline and water | |
| Sparks et al. | Synthesis of potential inhibitors of hemagglutination by influenza virus: chemoenzymic preparation of N-5 analogs of N-acetylneuraminic acid. | |
| WO2010116317A1 (en) | 6"-sialyllactose salts and process for their synthesis and for the synthesis of other a-sialyloligosaccharides | |
| JP3725198B2 (ja) | ピリピロペン誘導体 | |
| Liav et al. | Synthesis of bromoindolyl 4, 7-di-O-methyl-Neu5Ac: specificity toward influenza A and B viruses | |
| US9187513B2 (en) | N-substituted mannosamine derivatives, process for their preparation and their use | |
| WO2001025246A2 (en) | Chromogenic substrates of sialidase of bacterial, viral, protozoa, and vertebrate origin and methods of making and using the same | |
| Benzing-Nguyen et al. | Stepwise synthesis of N-acetylneuraminic acid and N-acetyl [1-13C] neuraminic acid | |
| JP2003522113A (ja) | シアリダーゼの発色基質とその製造法および使用法 | |
| US6303764B1 (en) | Synthesis of 4,7-dialkyl chromogenic glycosides of N-acetylneuraminic acids | |
| JPH0655753B2 (ja) | 新規オリゴグルコシド誘導体、α‐アミラーゼの測定方法および測定試薬 | |
| JP4015710B2 (ja) | 新規擬似糖脂質 | |
| US6420552B1 (en) | Syntheses of 4-alkyl chromogenic glycosides and 7-alkyl chromogenic glycosides of N-acetylneuraminic acids | |
| JP2018030801A (ja) | シアル酸誘導体、その製造方法及びそれを利用したシアリダーゼ阻害剤、抗菌剤、抗ウイルス剤 | |
| Sabesan | Synthesis and neuraminidase inhibition studies of 4-azido, amino, and acetamido substituted sialosides | |
| Bandgar et al. | Synthesis of methyl 4-acetamido-N-acetyl-4-deoxy-α-and β-4-epi-neuraminic acids | |
| JP4890805B2 (ja) | コア3型構造を有するo−結合型糖アミノ酸誘導体およびその製造方法 | |
| WO2025088529A1 (en) | N-derivatized sialic acids and related sialosides | |
| JP3992510B2 (ja) | 新規ラクトサミン誘導体とその製造方法 | |
| Spaltenstein et al. | synthesis of Potential Inhibitors of Hemaggtutination by In {uenza virus: chemoenzymic prep" a? ation of N'5 Analogs of tr/-Acetylneuraminii Acid. r | |
| MXPA98004081A (en) | 4,7-dialkoxy-n-acetylneuraminic acid derivatives and methods for detection of influenza type a and b viruses in clinical specimens | |
| JPS6360749B2 (ja) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060808 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061108 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070327 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070413 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |